URG Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
URG is not a good buy right now for an impatient investor. The stock is selling off hard (down -7.37% in the regular session) with weakening momentum signals (MACD negative and expanding) and it’s trading below the key pivot (1.876) and close to support (S1 1.753). Without an Intellectia buy signal today, the setup favors waiting for a momentum reversal (e.g., reclaiming the pivot/holding above support) rather than buying into a breakdown.
Price/Trend: Sharp down day (-7.37% regular session) despite still-bullish longer-term moving average structure (SMA_5 > SMA_20 > SMA_200), suggesting the broader trend may be up but the near-term tape is risk-off. Momentum: MACD histogram is -0.0085 and negatively expanding (bearish acceleration). RSI(6)=39.6 is neutral-to-weak (not oversold enough to signal a high-conviction bounce). Levels: Pivot 1.876 (price ~1.777 post-market, below pivot). Immediate support S1 1.753 (very close); if that fails, next support S2 1.678. Resistance levels: R1 1.998 then R2 2.073. Pattern-based forward view: Similar-pattern stats imply ~70% chance of -1.62% next day, +0.68% next week, and +13.83% next month—near-term caution with a more constructive 1-month skew.
Intellectia Proprietary Trading Signals
Potential event catalyst: Next earnings (QDEC
scheduled for 2026-02-10 pre-market.
and near critical support (1.753), raising breakdown risk.
Latest quarter: 2025/Q3. Revenue was $6.323M (-1.20% YoY), showing slight top-line contraction. Net income improved YoY to -$27.463M (up 243.2% YoY) and EPS improved to -0.07 (up 250% YoY), but profitability remains negative. Gross margin deteriorated to -11.7% (down 195.12% YoY), which is a clear operational/price-cost headwind. Overall: some loss improvement, but the business is still not producing healthy margins.
Recent analyst trend: Ratings are bullish and price targets remain above the current price. Texas Capital initiated coverage (2025-12-18) with a Buy and $2 PT. H.C. Wainwright reiterated Buy but trimmed PT slightly to $2.60 from $2.70 after Q3 (2025-11-04). Wall Street pros: uranium production footprint and perceived leverage to higher contracted volumes in 2026. Wall Street cons: financial/margin weakness today and execution risk in translating uranium market strength into sustained profitability. Influential/political trading: No recent congress trading data available; hedge fund and insider trends are neutral.
